Overhaul drug development to refill pipelines, expert says

08/16/2012 | Forbes

Recent failures of highly anticipated drugs show that Big Pharma should "develop a more flexible approach to drug approval and patent exclusivity and change its business model to encourage more scientific collaboration among companies," writes Christopher Bowe, a U.S. health care analyst at Informa Scrip. Working more closely with regulators and payers, accepting sliding patent exclusivity based on comparative effectiveness, and loosening intellectual property protections to encourage more collaboration would help Big Pharma out of the doldrums, Bowe writes.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY